Hydrocortisone acetate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1951
- First approval year
- 1951
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Hydrocortisone acetate
- Molecular weight
- 404.5
- Structure (SMILES)
- CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
- barquinol hc
- Barquinol hc
- chloromycetin hydrocort
- Chloromycetin hydrocort
- colifoam
- Colifoam
- cortef acetate
- Cortef acetate
- cortifoam
- Cortifoam
- cortril
- Cortril
- cortucid
- Cortucid
- dricort
- Dricort
- epifoam
- Epifoam
- framycort
- Framycort
- fucidin h
- Fucidin h
- genticin hc
- Genticin hc
- gentisone hc
And 51 more, listed on the interactive page.
- carmol hc component hydrocortisone acetate
- CARMOL HC COMPONENT HYDROCORTISONE ACETATE
- chloromycetin hydrocortisone component hydrocortisone acetate
- CHLOROMYCETIN HYDROCORTISONE COMPONENT HYDROCORTISONE ACETATE
- coly mycin s component hydrocortisone acetate
- COLY-MYCIN S COMPONENT HYDROCORTISONE ACETATE
- cor oticin component hydrocortisone acetate
- COR-OTICIN COMPONENT HYDROCORTISONE ACETATE
- cortisol 21 acetate
- Cortisol 21-acetate
- epifoam component hydrocortisone acetate
- EPIFOAM COMPONENT HYDROCORTISONE ACETATE
- hydrocortisone 21 acetate
- hydrocortisone 21 acetate mi
- Hydrocortisone 21-acetate
- HYDROCORTISONE 21-ACETATE [MI]
- hydrocortisone acetate
- Hydrocortisone acetate
- HYDROCORTISONE ACETATE [EP IMPURITY]
- HYDROCORTISONE ACETATE [EP MONOGRAPH]
- HYDROCORTISONE ACETATE [GREEN BOOK]
- HYDROCORTISONE ACETATE [JAN]
- HYDROCORTISONE ACETATE [MART.]
- HYDROCORTISONE ACETATE [ORANGE BOOK]
- HYDROCORTISONE ACETATE [USP MONOGRAPH]
And 41 more, listed on the interactive page.
- CAS registry numbers
- 50-03-3
- ChEMBL ID
- CHEMBL1091
- InChIKey
- ALEXXDVDDISNDU-JZYPGELDSA-N
- PubChem compound IDs
- 5744
- FDA ingredient codes (UNII)
- 3X7931PO74
- 27197
- 1007334
- Applicant
- PH HEALTH
- Approval date
- 17 May 1962
- Application number
- NDA050356
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Drug name stem
- -cort-
Administration routes
- Parenteral
- topical
Mechanisms of action
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Protein identifier
- P04150
Open Targets mechanisms
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Skin Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000701
- Subject identifier
- D012871
- Condition
- Vitiligo
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004208
- Subject identifier
- D014820
- Condition
- Hemorrhoids
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009552
- Subject identifier
- D006484
- Condition
- Pruritus
- Highest recorded phase
- 4
- Condition identifier
- HP:0000989
- Subject identifier
- D011537
- Condition
- Depressive Disorder
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0002050
- Subject identifier
- D003866
- Condition
- Inflammation
- Highest recorded phase
- 4
- Condition identifier
- MP:0001845
- Subject identifier
- D007249
- Condition identifier
- EFO_0000701
- Condition identifier
- EFO_0009552
- Highest recorded phase
- 2
- Condition identifier
- HP_0000989
- Condition identifier
- HP_0000989
- Highest recorded phase
- 4
- Condition identifier
- HP_0001072
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002050
- Condition identifier
- MONDO_0004872
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005093
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 3
- Condition identifier
- MP_0001845
- Condition identifier
- MP_0001845
- Highest recorded phase
- 4
- Event
- abdominal discomfort
- Reports
- 577
- Reporting signal score
- 753.015
- Event
- adrenal insufficiency
- Reports
- 170
- Reporting signal score
- 350.215
- Event
- adrenocortical insufficiency acute
- Reports
- 78
- Reporting signal score
- 249.692
- Event
- alopecia
- Reports
- 577
- Reporting signal score
- 745.521
- Event
- anti-cyclic citrullinated peptide antibody positive
- Reports
- 419
- Reporting signal score
- 1,657.37
- Event
- arthralgia
- Reports
- 589
- Reporting signal score
- 255.3
- Event
- arthropathy
- Reports
- 486
- Reporting signal score
- 877.94
- Event
- blister
- Reports
- 222
- Reporting signal score
- 267.455
- Event
- condition aggravated
- Reports
- 564
- Reporting signal score
- 312.771
- Event
- discomfort
- Reports
- 442
- Reporting signal score
- 920.384
- Event
- drug hypersensitivity
- Reports
- 1,411
- Reporting signal score
- 1,838.48
- Event
- drug intolerance
- Reports
- 550
- Reporting signal score
- 667.326
- Event
- duodenal ulcer perforation
- Reports
- 219
- Reporting signal score
- 766.529
- Event
- fatigue
- Reports
- 836
- Reporting signal score
- 220.455
- Event
- febrile bone marrow aplasia
- Reports
- 282
- Reporting signal score
- 910.665
- Event
- febrile neutropenia
- Reports
- 311
- Reporting signal score
- 302.704
- Event
- folliculitis
- Reports
- 120
- Reporting signal score
- 274.319
- Event
- frequent bowel movements
- Reports
- 114
- Reporting signal score
- 178.736
- Event
- general physical health deterioration
- Reports
- 210
- Reporting signal score
- 140.678
- Event
- glossodynia
- Reports
- 484
- Reporting signal score
- 1,432.17
- Event
- hand deformity
- Reports
- 469
- Reporting signal score
- 1,563.45
- Event
- helicobacter infection
- Reports
- 223
- Reporting signal score
- 667.702
- Event
- hepatic enzyme increased
- Reports
- 440
- Reporting signal score
- 629.532
- Event
- hip arthroplasty
- Reports
- 143
- Reporting signal score
- 283.355
- Event
- hypersensitivity
- Reports
- 574
- Reporting signal score
- 550.844
And 28 more, listed on the interactive page.
- NCT00801957
- NCT04615962
- NCT02689856
- NCT03335774
- NCT02837432
- NCT04148261
- NCT03358082
- Route
- Rectal
- How often
- Twice daily
- Insert one suppository in the rectum
- Pointed end first
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 100.9
- Calculated partition coefficient (ALogP)
- 2.35
- Calculated partition coefficient (XLogP)
- 2.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 29
- Molecular formula
- C23H32O6
- Monoisotopic mass
- 404.21988874
- Natural product
- Yes
- 0037-6822
- 0037-6824
- 0037-6830
- 0574-7090
- 0574-7093
- 0713-0493
- 0713-0503
- 0904-7340
- 10135-751
- 13925-160
- 13925-163
- 13925-164
- 13925-165
- 16477-201
- 16477-202
- 16571-164
- 16571-676
- 24470-964
- 24470-965
- 24689-102
- 24689-103
- 28595-050
- 39328-029
- 39328-129
- 44118-704
And 62 more, listed on the interactive page.
- Recorded assays
- 1,695
- Active assays
- 15
- Confirmatory
- Screening
- Anti-Inflammatory Agents
Distribution coefficient (LogD)
- Median
- 2.19
- Mean
- 2.175
- Minimum
- 2.11
- Maximum
- 2.21
- Unit
- unitless
- Assays
- 4
- Standard deviation
- 0.0443471
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Related records
Trials (346)
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
- 506U78 in Treating Patients With Refractory Hematologic Cancer
- A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone
- A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension
- A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome
- A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer
- A Pilot Study Into Health Pre and Post Treatment With Intravenous Aminophylline and Hydrocortisone in Severe Asthmatics
- A Pilot Trial of Pediatric Liver Transplantation Without Steroids
- A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars
- A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis
- A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas
- A Study in Adults With Untreated Acute Lymphoblastic Leukemia
- A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
- A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
- A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
Approved for (1)
In development for (4)
- Atopic eczema Phase 2
- Depressive disorder Early phase 1
- Hemorrhoid Phase 2
- Vitiligo Phase 1
Targets (1)
- NR3C1 Glucocorticoid receptor agonist